Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

Author:

Papp K.¹,Thaçi D.²,Reich K.³,Riedl E.⁴,Langley R.G.⁵,Krueger J.G.⁶,Gottlieb A.B.⁷,Nakagawa H.⁸,Bowman E.P.⁹,Mehta A.⁹,Li Q.⁹,Zhou Y.⁹,Shames R.⁹

Affiliation:

1. Probity Medical Research; 135 Union Street East Waterloo ON N2J 1C4 Canada

2. Comprehensive Center for Inflammation Medicine; University Medical School Schleswig-Holstein; University of Lübeck; Lübeck Germany

3. SCIderm Research Institute and Dermatologikum Hamburg; Hamburg Germany

4. Division of General Dermatology; Department of Dermatology; Medical University of Vienna; Vienna Austria

5. Dalhousie University; Halifax NS Canada

6. Laboratory for Investigative Dermatology; The Rockefeller University; New York NY U.S.A

7. Department of Dermatology; Tufts Medical Center; Boston MA U.S.A

8. Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan

9. Merck & Co., Inc.; Kenilworth NJ U.S.A

Funder

Merck

Publisher

Wiley

Subject

Dermatology

Link

Reference25 articles.

1. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey;Krueger;Arch Dermatol,2001

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献